---
title: "Sotagliflozin “shows new mechanism of action” in reducing heart attack and stroke among diabetics, kidney disease patients"
date: "2025-02-15T08:00:08.000Z"
publishedDate: "15 février 2025"
summary: "Sotagliflozin, a recently-US Food and Drug Administration (FDA) approved drug for the treatment of type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results of an international clinical trial published in The Lancet Diabetes &#38; Endocrinology. Sotagliflozin is a sodium-glucose cotransporter [&#8230;] The post Sotagliflozin “shows new mechanism of action” in reducing heart attack and stroke among diabetics, kidney disease patients appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/sotagliflozin-shows-new-mechanism-of-action-in-reducing-heart-attack-and-stroke-among-diabetics-kidney-disease-patients/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-02-15-sotagliflozin-shows-new-mechanism-of-action-in-reducing-heart-attack-and-stroke-among-diabetics-kidney-disease-patients"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2020/03/Deepak-L.-Bhatt-WEB.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/sotagliflozin-shows-new-mechanism-of-action-in-reducing-heart-attack-and-stroke-among-diabetics-kidney-disease-patients/"
---

![Sotagliflozin “shows new mechanism of action” in reducing heart attack and stroke among diabetics, kidney disease patients](https://cardiovascularnews.com/wp-content/uploads/sites/14/2020/03/Deepak-L.-Bhatt-WEB.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/sotagliflozin-shows-new-mechanism-of-action-in-reducing-heart-attack-and-stroke-among-diabetics-kidney-disease-patients/*

## L’essentiel

Sotagliflozin, a recently-US Food and Drug Administration (FDA) approved drug for the treatment of type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results of an international clinical trial published in The Lancet Diabetes &#38; Endocrinology. Sotagliflozin is a sodium-glucose cotransporter [&#8230;] The post Sotagliflozin “shows new mechanism of action” in reducing heart attack and stroke among diabetics, kidney disease patients appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/sotagliflozin-shows-new-mechanism-of-action-in-reducing-heart-attack-and-stroke-among-diabetics-kidney-disease-patients/
